Johnson Grants Let Scientists Take Risks

In 1989, when Harvard University geneticist Rachael Neve sought funding to test her controversial hypothesis on Alzheimer's disease, her requests fell on deaf ears. "I had been writing a proposal to [the National Institutes of Health] for a year and a half, and it kept getting rejected," recalls Neve, who challenged the conventional wisdom in neuroscience with data indicating that the toxic protein responsible for Alzheimer's was some 60 amino acids longer than previously thought. "I applied to

Written byPaul Kefalides
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Neve then learned of the Focused Giving program offered by health-care giant Johnson & Johnson of New Brunswick, N.J., a 12- year-old initiative that supports basic research at universities to the tune of $2.5 million a year. J&J took a chance on Neve's hypothesis. The company supported her for three years and lent its expertise in setting up a germ-free animal facility for Neve's research mice. The resulting animal model is silencing her critics, and the success has attracted the interest of NIH. Neve now has two additional grants to support her work.

J&J's Focused Giving program has just awarded its 100th grant. Among its recipients are Nobel laureates Baruch Blumberg of Philadelphia's Fox Chase Cancer Center; Gerald Edelman of the University of California, San Diego; and Michael Brown and Joseph Goldstein of the University of Texas, Dallas.

Grant recipients say they appreciate the exchange of ideas afforded by the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies